In the last years, there is great impetus to discover new biomarkers in RCC in order to address the patients toward an appropriate adjuvant therapy. In this regard, miR501-5p that is differentially expressed in RCC and mTOR which in many tumours correlates with a poor prognosis, could represent possible biomarkers. Therefore, miR501-5p expression and mTOR activity will be studied in normal and RCC tissues as well as in kidney cell lines depleted or enriched in miR501-5p sequences. Cell growth, apoptosis, autophagy and related signaling pathways will be analyzed in kidney cells and tissues expressing different levels of miR501-5p in order to evaluate the role of miR501-5p in RCC. High and low miR501-5p expression levels combined with mTOR activity of different RCC tissues will be matched with the outcome of RCC patients to evaluate their possible prognostic role.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||A combination of miR501-5p and mTOR as molecular markers for the prognosis of renal carcinomas|
|Data di pubblicazione:||2014|
|???metadata.dc.relation.allfinancing???:||MINISTERO DELLA SALUTE|
|Appare nelle tipologie:||08.1 Coordinamento Prog.Ricerca Naz. ed Internaz.|